{
  "id": "6211575f3a8413c653000011",
  "type": "summary",
  "question": "What is the indication of CPX-351?",
  "ideal_answer": "CPX-351 has been approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/34256819"
  ],
  "snippets": [
    {
      "text": "CPX-351 (United States: Vyxeos\u00ae; Europe: Vyxeos\u00ae Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34256819",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}